



HHS PUBLIC ACCESS

Author manuscript

Pediatr Res. Author manuscript; available in PMC 2017 October 18.

Published in final edited form as:

Pediatr Res. 2017 January ; 81(1-1): 88–93. doi:10.1038/pr.2016.179.

Antenatal Corticosteroids and the Renin-Angiotensin-Aldosterone System in Adolescents Born Preterm

Andrew M. South^{*,1,2}, Patricia A. Nixon^{1,3}, Mark C. Chappell^{2,4}, Debra I. Diz^{2,4}, Gregory B. Russell⁵, Beverly M. Snively⁵, Hossam A. Shaltout^{2,6}, James C. Rose⁶, T. Michael O'Shea^{2,7}, and Lisa K. Washburn^{1,2}

¹Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, North Carolina, USA

²Hypertension and Vascular Research Center, Wake Forest School of Medicine, Winston Salem, North Carolina, USA

³Department of Health and Exercise Science, Wake Forest University, Winston Salem, North Carolina, USA

⁴Department of Surgery, Wake Forest School of Medicine, Winston Salem, North Carolina, USA

⁵Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston Salem, North Carolina, USA

⁶Department of Obstetrics and Gynecology, Wake Forest School of Medicine, Winston Salem, North Carolina, USA

⁷Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

Abstract

Background—Antenatal corticosteroid (ANCS) treatment hastens fetal lung maturity and improves survival of premature infants, but the long-term effects of ANCS are not well-described. Animal models suggest ANCS increases the risk of cardiovascular disease through programmed changes in the renin-angiotensin (Ang)-aldosterone system (RAAS). We hypothesized that ANCS exposure alters the RAAS in adolescents born prematurely.

Methods—A cohort of 173 adolescents born prematurely was evaluated, of whom 92 were exposed to ANCS. We measured plasma and urine Ang II and Ang-(1–7) and calculated Ang II/Ang-(1–7) ratios. We used general linear regression models to estimate the difference in the RAAS between the ANCS-exposed and unexposed groups, adjusting for confounding variables.

Results—In unadjusted analyses, and after adjustment for sex, race, and maternal hypertension, ANCS exposure was associated with increased urinary Ang II/Ang-(1–7) [estimate 0.27 (95% CI

*Corresponding Author: Andrew M. South, MD, MS, Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine, One Medical Center Boulevard, Winston Salem, NC 27157, Phone (336) 716-9640, Fax (336) 716-9229, asouth@wakehealth.edu.

Potential Conflicts of Interest: The authors have no conflicts of interest relevant to this article to disclose.

Category of Study: Translational research

0.03, 0.5), $p = 0.03$], increased plasma Ang-(1–7) [0.66 (0.26, 1.07), $p = 0.002$], and decreased plasma Ang II/Ang-(1–7) [–0.48 (–0.91, –0.06), $p = 0.03$].

Conclusions—These alterations indicate an imbalance in the urinary RAAS, promoting the actions of Ang II at the expense of Ang-(1–7), which over time may increase the risk of renal inflammation and fibrosis and ultimately hypertension and renal disease.

Introduction

Antenatal corticosteroids (ANCS), given to pregnant women expected to deliver prematurely to accelerate fetal lung maturity, increases survival and improves outcomes in the offspring, but the long-term effects of ANCS are not well-characterized (1–3). Data from preclinical models that simulate human exposure suggest that ANCS may increase the risk for hypertension (HTN) and cardiovascular disease (4, 5). The increased risk may be mediated in part by chronic dysregulation of the renin-angiotensin (Ang)-aldosterone system (RAAS), leading to increased renal and cardiovascular disease in adulthood (6, 7). Human studies offer conflicting conclusions regarding relationships between ANCS exposure and cardiovascular outcomes in adolescents and young adults and have not evaluated the effect of ANCS exposure on the RAAS (8–12).

The RAAS includes the Ang-converting enzyme (ACE)/Ang II pathway and the ACE2/Ang-(1–7) pathway, is important in renal and cardiovascular development, and is subject to developmental changes early in life (13, 14). Ang II is a vasoconstrictor, enhances sodium retention directly and through stimulation of aldosterone, and promotes inflammation and fibrosis, while Ang-(1–7) has variable effects on sodium transport and glomerular filtration and has anti-inflammatory and anti-fibrotic effects in numerous organ systems, including the kidney (6, 15–19). An altered RAAS is associated with adverse health outcomes, including HTN and chronic kidney disease (20). RAAS components measured in the urine are markers of the intrarenal RAAS (21–23). We measured RAAS components in adolescents born prematurely to evaluate the hypothesis that ANCS exposure is associated with long-term alteration of the balance between Ang II and Ang-(1–7) in plasma and urine.

Results

Study Population (Table 1)

Reflective of the larger ANCS study's design, approximately half the study sample was born to mothers who received ANCS (53%). The majority of subjects were female (55%), 43% were black, and 35% were overweight/obese at 14 years of age. Maternal HTN complicated 36% of pregnancies. Blacks were less likely to receive ANCS. The ANCS group had a higher rate of maternal HTN and was taller.

ANCS Exposure and Urinary RAAS

There were no differences in Ang II, Ang II/creatinine, Ang-(1–7), or Ang-(1–7)/creatinine (Table 1). Ang II/Ang-(1–7) was higher in the ANCS group and this difference persisted when adjusting for race, sex, and maternal HTN [estimate 0.27 (95% CI 0.03, 0.5), $p = 0.03$] (Table 2).

ANCS Exposure and Plasma RAAS

There were no differences in plasma renin activity (PRA), aldosterone, aldosterone-to-renin ratio (ARR), or Ang II (Table 1). The ANCS group had higher plasma Ang-(1–7) and lower Ang II/Ang-(1–7), and these differences persisted when adjusted for race, sex, and maternal HTN [Ang-(1–7): 0.66 (0.26, 1.07), $p = 0.002$; Ang II/Ang-(1–7): -0.48 (-0.91 , -0.06), $p = 0.03$] (Table 2, Figure 1). The associations of ANCS with higher plasma Ang-(1–7) and lower Ang II/Ang-(1–7) were stronger among black study participants (Figure 2) [Ang-(1–7): 1.13 (0.61, 1.66), $p < 0.001$; Ang II/Ang-(1–7): -0.91 (-1.48 , -0.33), $p = 0.003$].

Although log-transformed waist-to-height ratio was associated with both plasma Ang-(1–7) and Ang II/Ang-(1–7) [-1.44 (-2.65 , -0.23), $p = 0.02$; 2.26 (1.04, 3.47), $p < 0.001$], adding waist-to-height ratio to the regression models did not substantially alter the association between ANCS and plasma RAAS.

Discussion

Among adolescents born prematurely, ANCS exposure was associated with increased urinary Ang II/Ang-(1–7), increased plasma Ang-(1–7), and decreased plasma Ang II/Ang-(1–7). The increased urinary Ang II/Ang-(1–7) among preterm adolescents exposed to ANCS may be due to a higher renal (urinary) Ang II. This shift in the kidney, towards Ang II and away from Ang-(1–7), is consistent with the finding that offspring of pregnant ewes exposed to clinically relevant doses of ANCS (betamethasone given at 0.6 gestation: the equivalent of about 24 weeks gestation in humans) develop alterations in the renal RAAS, decreased renal function, and elevated blood pressure as adults. RAAS alterations include attenuated responses to Ang-(1–7), enhanced responses to Ang II, increased expression of the Ang II type 1 receptor, increased serum ACE activity, decreased serum ACE2 activity, and decreased proximal tubular ACE2 activity and expression. Together these alterations indicate an imbalance in the RAAS which promotes the actions of Ang II at the expense of Ang-(1–7) (6, 7, 24, 25).

Over time, elevated renal Ang II levels could increase the risk for renal inflammation and fibrosis and may lead to HTN and renal disease (26). This mechanism could accentuate other perinatal renal insults such as ischemia and nephrotoxic exposure (21, 27). In contrast to RAAS alterations in urine, plasma levels of Ang-(1–7) were higher among ANCS-exposed adolescents, which might serve to attenuate the physiologic effects of an elevated Ang II to Ang-(1–7) ratio in the kidney. A potential explanation for this finding is that it may reflect a compensatory upregulation to counteract further inflammation and fibrosis by Ang II as ACE2 expression and elevated Ang-(1–7) levels are evident in several pathologic states (28, 29). ANCS exposure could also directly lead to increased systemic or vascular ACE2/Ang-(1–7) pathway activity.

Consistent with data showing obesity is associated with an upregulated ACE/Ang II pathway (30), we found that waist-to-height ratio, a measure of central adiposity, was associated with decreased plasma Ang-(1–7) and increased plasma Ang II/Ang-(1–7). Obesity-driven RAAS dysregulation is associated with inflammation, insulin resistance, and metabolic disease (31). Racial differences in PRA and aldosterone are well-documented. Our finding that

associations between ANCS and the RAAS were stronger among black study participants suggests the possibility that long-term effects of ANCS might differ for blacks and non-blacks.

Our study is limited by the non-randomized allocation of the exposure (ANCS), leaving open the possibility of confounding due to factors we did not measure. We could not fully account for all the potential factors that influence the RAAS, such as genetic influences and dietary variability. Further, we lack measurements of RAAS enzymatic activity, specifically ACE and ACE2, which could better characterize the profiles of the ACE/Ang II and ACE2/Ang-(1-7) pathways in this cohort.

In conclusion, in a cohort of adolescents born prematurely, ANCS exposure was associated with alterations in the RAAS, specifically increased urinary Ang II/Ang-(1-7), increased plasma Ang-(1-7), and decreased plasma Ang II/Ang-(1-7). An altered systemic and intrarenal RAAS may modify an individual's cardiovascular risk profile and negatively impact kidney function later in life.

Methods

Study Participants

Study participants were recruited from among living members of a premature birth cohort of 193 patients born between January 1, 1992 and June 30, 1996 at a regional perinatal center (Forsyth Medical Center in Winston Salem, NC). This cohort included i) children with whom we had contact through at least one year of age, ii) were not wards of the state, and iii) were successfully contacted at 14 years of age. Sixty-two percent of those contacted were enrolled ($n = 193$). Of the 193 cohort subjects, seven were excluded from the analysis (two were twins, three had congenital anomalies, and two had maternal oral steroid use). The members of the cohort were evaluated at 14 years of age as part of a larger study of ANCS exposure and cardiovascular and metabolic outcomes among preterm adolescents (Figure 3). We report the measurements made at the third study visit, at which 173 subjects were evaluated (92 of 94 in the ANCS group, 81 of 92 in the unexposed group). All the subjects provided urine specimens and 120 provided blood specimens. More detailed information on materials and methods, including specific inclusion and exclusion criteria, have been published previously (32). The Wake Forest School of Medicine and Forsyth Medical Center Institutional Review Boards approved the study. We obtained informed consent from parents or legal guardians and assent from participants.

Data Collection

Perinatal characteristics were recorded from medical records and research databases. We recorded the presence of maternal hypertension during pregnancy (maternal HTN) and ANCS exposure, defined as maternal treatment with betamethasone and/or dexamethasone (one subject's mother received dexamethasone only and one subject's mother received both betamethasone and dexamethasone). Birth characteristics were noted, including i) sex, ii) GA, and iii) birth weight. Birth weight z score was determined (33). We categorized subjects as born SGA if their birth weight percentile was less than or equal to the 10% (34).

Demographic information was recorded at 14 years of age, including parental-reported race (black vs non-black), and height, weight, and waist circumference were measured. We calculated BMI (kg/m^2) and waist-to-height ratio, and defined overweight/obese as BMI $\geq 85\%$ for age and sex (35). Sexual maturity was rated (1 to 5) using a self-reported questionnaire completed in private and was summarized as the average of both determinants of secondary sexual characteristics (external genitalia development and pubic hair in males; breast development and pubic hair in females) (36). Resting blood pressure was measured with a mercury manometer after the subject was seated quietly for at least five minutes, and the average of three measurements was recorded according to established guidelines (37). Blood pressure z scores were calculated (38).

Laboratory Measurements

Blood was collected from participants in the seated position to measure PRA, aldosterone, Ang-(1–7), and Ang II. A spot urine sample was provided to measure Ang-(1–7), Ang II, and creatinine. We calculated ARR, the Ang II/Ang-(1–7) ratio in the plasma and urine, and the urinary Ang-(1–7) and Ang II concentrations corrected for creatinine. Specific laboratory methods have been published previously (39).

Statistical Analyses

Distributions of continuous variables were described with the mean and *SD* or the median and IQR. We used natural logarithmic transformation to improve the distributional characteristics of the continuous variables when appropriate. Values below the minimum detectable thresholds were assigned one-half those threshold values (39). For between-group comparisons of continuous variables, we used the t-test and Wilcoxon Rank-Sum test; for comparisons of categorical variables we used the Chi-square and Fisher's Exact tests. Correlations were assessed with Pearson or Spearman correlation coefficients.

We used general linear regression models to evaluate the relationship of ANCS exposure and RAAS outcomes. We evaluated effect modification using product terms (ANCS \times modifier). To identify variables that might confound the ANCS – RAAS relationships we evaluated bivariate relationships between each potential confounder and ANCS and each potential confounder and RAAS outcome. Potential confounders were included in the multivariate models if either of the following were found: i) an association with both the RAAS measure and ANCS at $p < 0.2$, or ii) a $>10\%$ change in the regression coefficient for ANCS estimated with general linear models. In addition, sex, race, and maternal HTN were identified a priori as potential confounders and effect modifiers, based on the results of previous studies (39, 40). The criterion for inclusion in the final multivariate model was $p < 0.05$. For comparisons of the ANCS-exposed and unexposed groups, a two-sided alpha of 0.05 was considered statistically significant. We used Enterprise Guide software, Version 7.11 of the SAS System for Windows (SAS Institute Inc., Cary, NC) for all analyses.

Acknowledgments

We thank the participants and their families, Patricia Brown, RN, research nurse, and Alice Scott, RN, research study coordinator.

Statement of Financial Support: This study is funded by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (PO1 HD047584; HD084227), the Clinical Research Unit of Wake Forest Baptist Medical Center (MCRR/NIH MO1-RR07122), and the Forsyth Medical Center and Wake Forest School of Medicine Department of Pediatrics research funds.

References

1. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. *Pediatrics*. 1972; 50:515–525. [PubMed: 4561295]
2. Doran TA, Swyer P, MacMurray B, et al. Results of a double-blind controlled study on the use of betamethasone in the prevention of respiratory distress syndrome. *Am J Obstet Gynecol*. 1980; 136:313–320. [PubMed: 7352521]
3. Gilstrap LC, Christensen R, Clewell WH, et al. Effect of corticosteroids for fetal maturation on perinatal outcomes: NIH consensus development panel on the effect of corticosteroids for fetal maturation on perinatal outcomes. *JAMA*. 1995; 273:413–418. [PubMed: 7823388]
4. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CRW. Glucocorticoid exposure in utero: new model for adult hypertension. *Lancet*. 1993; 341:339–341. [PubMed: 8094115]
5. Dodic M, May CN, Wintour EM, Coghlan JP. An early prenatal exposure to excess glucocorticoid leads to hypertensive offspring in sheep. *Clin Sci (Lond)*. 1998; 94:149–155. [PubMed: 9536923]
6. Shaltout HA, Figueroa JP, Rose JC, Diz DI, Chappell MC. Alterations in circulatory and renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 in fetal programmed hypertension. *Hypertension*. 2009; 53:404–408. [PubMed: 19047579]
7. Gwathmey TM, Shaltout HA, Rose JC, Diz DI, Chappell MC. Glucocorticoid-induced fetal programming alters the functional complement of angiotensin receptor subtypes within the kidney. *Hypertension*. 2011; 57:620–626. [PubMed: 21220702]
8. Doyle LW, Ford GW, Davis NM, Callanan C. Antenatal corticosteroid therapy and blood pressure at 14 years of age in preterm children. *Clin Sci (Lond)*. 2000; 98:137–142. [PubMed: 10657267]
9. Kelly BA, Lewandowski AJ, Worton SA, et al. Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism. *Pediatrics*. 2012; 129:e1282–1290. [PubMed: 22508917]
10. Dessens AB, Smolders-de Hass H, Koppe JG. Twenty-year follow-up of antenatal corticosteroid treatment. *Pediatrics*. 2000; 105
11. Finken MJJ, Keijzer-Veen MG, Dekker FW, et al. Antenatal glucocorticoid treatment is not associated with long-term metabolic risks in individuals born before 32 weeks of gestation. *Arch Dis Child Fetal Neonatal Ed*. 2008; 93:F442–F447. [PubMed: 18450806]
12. Dalziel SR, Walker NK, Parag V, et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. *Lancet*. 2005; 365:1856–1862. [PubMed: 15924982]
13. Carbone GM, Sheikh AU, Rogers S, Brewer G, Rose JC. Developmental changes in renin gene expression in ovine kidney cortex. *Am J Physiol*. 1993; 264:R591–R596. [PubMed: 8457013]
14. Woods LL, Rasch R. Perinatal ang II programs adult blood pressure, glomerular number, and renal function in rats. *Am J Physiol*. 1998; 275:R1593–R1599. [PubMed: 9791078]
15. Xue H, Zhou L, Yuan P, et al. Counteraction between angiotensin II and angiotensin-(1–7) via activating angiotensin type I and mas receptor on rat renal mesangial cells. *Regul Pept*. 2012; 177:12–20. [PubMed: 22561449]
16. Benter IF, Yousif MHM, Anim JT, Cojocel C, Diz DI. Angiotensin-(1–7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with l-NAME. *Am J Physiol Heart Circ Physiol*. 2006; 290:H684–H691. [PubMed: 16403946]
17. Benter IF, Yousif MHM, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1–7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. *Am J Nephrol*. 2008; 28:25–33. [PubMed: 17890855]

18. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the angiotensin converting enzyme 2-angiotensin (1–7)-mas receptor axis: fetal programming, sex differences, and intracellular pathways. *Front Endocrinol (Lausanne)*. 2013; 4:201.
19. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1–7). *Hypertension*. 1997; 30:535–541. [PubMed: 9322978]
20. Simões e Silva AC, Diniz JSS, Pereira RM, Pinheiro SVB, Santos RAS. Circulating renin angiotensin system in childhood chronic renal failure: marked increase of angiotensin-(1–7) in end-stage renal disease. *Pediatr Res*. 2006; 60:734–739. [PubMed: 17065573]
21. Allred AJ, Chappell MC, Ferrario CM, Diz DI. Differential actions of renal ischemic injury on the intrarenal angiotensin system. *Am J Physiol Renal Physiol*. 2000; 279:F636–645. [PubMed: 10997913]
22. Xiao F, Hiremath S, Knoll G, et al. Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes. *PLoS ONE*. 2012; 7:e37649. [PubMed: 22629438]
23. Kasper SO, Basso N, Kurnjek ML, et al. Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. *Am J Nephrol*. 2005; 25:335–341. [PubMed: 15976496]
24. Bi J, Contag SA, Carey LC, et al. Antenatal betamethasone exposure alters renal responses to angiotensin-(1–7) in uninephrectomized adult male sheep. *J Renin Angiotensin Aldosterone Syst*. 2013; 14:290–298. [PubMed: 23161144]
25. Contag SA, Bi J, Chappell MC, Rose JC. Developmental effect of antenatal exposure to betamethasone on renal angiotensin II activity in the young adult sheep. *Am J Physiol Renal Physiol*. 2010; 298:F847–F856. [PubMed: 20071463]
26. Dilauro M, Zimpelmann J, Robertson SJ, Genest D, Burns KD. Effect of ACE2 and angiotensin-(1–7) in a mouse model of early chronic kidney disease. *Am J Physiol Renal Physiol*. 2010:F1523–1532. [PubMed: 20357030]
27. Vieux R, Fresson J, Guillemin F, Hascoet JM. Perinatal drug exposure and renal function in very preterm infants. *Arch Dis Child Fetal Neonatal Ed*. 2011; 96:F290–F295. [PubMed: 21173011]
28. Epelman S, Shrestha K, Troughton RW, et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. *J Card Fail*. 2009; 15:565–571. [PubMed: 19700132]
29. Yamaleyeva LM, Gilliam-Davis S, Almeida I, Brosnihan KB, Lindsey SH, Chappell MC. Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes. *Am J Physiol Renal Physiol*. 2012; 302:F1374–F1384. [PubMed: 22378820]
30. Engeli S, Böhnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. *Hypertension*. 2005; 45:356–362. [PubMed: 15630041]
31. Underwood P, Adler G. The renin angiotensin aldosterone system and insulin resistance in humans. *Curr Hypertens Rep*. 2013; 15:59–70. [PubMed: 23242734]
32. Washburn L, Nixon P, Russell G, Snively BM, O’Shea TM. Adiposity in adolescent offspring born prematurely to mothers with preeclampsia. *J Pediatr*. 2013; 162:912–917.e911. [PubMed: 23211927]
33. Oken E, Kleinman KP, Rich-Edwards J, Gillman MW. A nearly continuous measure of birth weight for gestational age using a United States national reference. *BMC Pediatr*. 2003; 3:6. [PubMed: 12848901]
34. Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. *J Pediatr*. 1967; 71:159–163. [PubMed: 6029463]
35. Barlow SE. Expert Committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. *Pediatrics*. 2007; 120(Suppl 4):S164–192. [PubMed: 18055651]
36. Taylor SJ, Whincup PH, Hindmarsh PC, Lampe F, Odoki K, Cook DG. Performance of a new pubertal self-assessment questionnaire: a preliminary study. *Paediatr Perinat Epidemiol*. 2001; 15:88–94. [PubMed: 11237120]
37. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. *National High*

- Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. *Pediatrics*. 1996; 98(4 Pt 1):649–658. [PubMed: 8885941]
38. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. *Am J Epidemiol*. 2008; 167:653–666. [PubMed: 18230679]
 39. Washburn LK, Brosnihan KB, Chappell MC, et al. The renin–angiotensin–aldosterone system in adolescent offspring born prematurely to mothers with preeclampsia. *J Renin Angiotensin Aldosterone Syst*. 2015; 16:529–538. [PubMed: 24737639]
 40. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. *Kidney Int*. 1999; 55:278–285. [PubMed: 9893137]




Figure 1.
 Relationship between ANCS and RAAS
 Gray arrows indicate direction of association with the RAAS: dark gray indicates upregulation of Ang II and light gray indicates upregulation of Ang-(1-7).




Figure 2.
 ANCS and RAAS Stratified by Race
 2a: Plasma Ang II/Ang-(1-7)
 2b: Plasma Ang-(1-7)
 * $p = 0.002$, ** $p < 0.001$. ANCS = dark gray; No ANCS = light gray. Bar denotes median, circle denotes mean, box indicates IQR, and whiskers include 1.5x IQR. Between-group comparisons by Wilcoxon Rank-Sum test.




Figure 3.
Study Participant Flow Diagram

Table 1

Clinical Characteristics and the Renin-Angiotensin-Aldosterone System Profile at 14 Years

Clinical Characteristics	All Subjects <i>N</i> = 173	ANCS 92 (53%)	No ANCS 81 (47%)
Male	78 (45%)	44 (48%)	34 (42%)
Black	74 (43%)	27 (29%)*	47 (58%)
Maternal Hypertension	63 (36%)	40 (43%)*	23 (28%)
GA (weeks)	27.8 (2.6)	27.7 (2.4)	27.9 (2.9)
Birth Weight (g)	1053 (265)	1033 (269)	1075 (261)
Birth Weight z Score	-0.29 (0.84)	-0.35 (0.74)	-0.22 (0.93)
SGA	21 (12%)	9 (10%)	12 (15%)
Height (cm)	161.6 (9.3)	163.2 (8.9)*	159.8 (9.5)
Weight (kg)	56.0 [47.5, 69.5]	56.6 [48.7, 68.6]	56.0 [46.3, 71.8]
BMI (kg/m ²)	21.1 [18.6, 26.5]	20.5 [18.4, 26.0]	22.5 [19.0, 26.6]
Overweight/Obese	60 (35%)	28 (30%)	32 (40%)
Waist-to-Height Ratio	0.46 [0.42, 0.53]	0.45 [0.42, 0.51]	0.48 [0.43, 0.54]
Sexual Maturity Rating ^a	4.5 [4.0, 5.0]	4.5 [4.0, 5.0]	4.5 [4.0, 5.0]
Systolic Blood Pressure	106.3 (9.9)	107.2 (10.4)	105.2 (9.2)
Systolic Blood Pressure z Score	-0.40 (0.89)	-0.36 (0.98)	-0.45 (0.79)
Diastolic Blood Pressure	61.3 (8.9)	61.6 (8.9)	60.9 (8.9)
Diastolic Blood Pressure z Score	-0.28 (0.78)	-0.26 (0.79)	-0.29 (0.77)
Urinary RAAS Profile	<i>N</i> = 173	<i>n</i> = 92	<i>n</i> = 81
Ang-(1-7) (pmol/L)	70.1 [48.6, 94.8]	70.9 [44.6, 94.4]	68.7 [49.0, 98.4]
Ang-(1-7)/Creatinine (pmol/g)	0.41 [0.31, 0.59]	0.39 [0.29, 0.61]	0.43 [0.33, 0.57]
Ang II (pmol/L)	9.3 [6.3, 15.3]	10.5 [6.5, 16.6]	8.7 [5.9, 13.8]
Ang II/Creatinine (pmol/g)	0.05 [0.04, 0.1]	0.06 [0.04, 0.11]	0.05 [0.03, 0.1]
Ang II/Ang-(1-7)	0.15 [0.1, 0.23]	0.17 [0.1, 0.27]*	0.14 [0.1, 0.19]
Plasma RAAS Profile	<i>N</i> = 120	<i>n</i> = 70	<i>n</i> = 50
PRA (pmol Ang I/L/h)	2.4 [1.2, 3.2]	2.5 [1.4, 3.2]	1.9 [1.0, 3.0]
Aldosterone (pmol/L)	9.9 [5.3, 14.1]	9.9 [6.2, 13.3]	9.9 [4.3, 17.8]
ARR (pmol/L per pmol Ang I/L/h)	4.2 [3.0, 6.6]	4.1 [3.1, 6.2]	4.6 [2.5, 8.7]
Ang-(1-7) (pmol/L)	5.6 [2.9, 13.5]	9.0 [2.6, 14.7]*	2.7 [1.4, 7.0]
Ang II (pmol/L)	21.5 [16.7, 32.1]	22.3 [17.1, 33.3]	21.0 [15.6, 29.1]
Ang II/Ang-(1-7)	3.7 [1.9, 6.8]	3.0 [1.6, 7.8]*	6.3 [3.5, 13.3]

N (%), mean (*SD*), median [IQR].^a*n* = 154.* Denotes significant difference between groups with *p* < 0.05 by chi-square test, t-test, or Wilcoxon Rank-Sum test.

Relationship Between Antenatal Corticosteroid Exposure and the Renin-Angiotensin-Aldosterone System

Table 2

	Unadjusted			Adjusted ^d			Stratified ^d		
	Estimate (95% CI)	p Value		Estimate (95% CI)	p Value		Estimate (95% CI)	p Value	
Urine Ang II/Ang-(1-7)	0.26 (0.04, 0.48)	0.02		0.27 (0.03, 0.5)	0.03	-	-	-	-
Plasma Ang II/Ang-(1-7)	-0.49 (-0.88, -0.11)	0.01		-0.48 (-0.91, -0.06)	0.03	Black ^b	-0.91 (-1.48, -0.33)	0.003	
						Non-Black ^c	-0.21 (-0.78, 0.36)	0.46	
Plasma Ang-(1-7)	0.65 (0.28, 1.02)	<0.001		0.66 (0.26, 1.07)	0.002	Black ^b	1.13 (0.61, 1.66)	<0.001	
						Non-Black ^d	0.37 (-0.18, 0.92)	0.19	

General linear regression models.

^a Adjusted for sex, race, and maternal HTN;

^b n = 15;

^c n = 54;

^d n = 55.